COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trialAll patients tolerated COMP360...

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression - Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse...

Guy Goodwin joins COMPASS Pathways as Chief Medical Officer COMPASS announces changes to its Executive Team London, UK – 29 July 2021         COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating...